Clinical trials: Neurodevelopmental Disorder (Diagnosis)
- Condition Neurodevelopmental Disorder (Diagnosis)
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Child Behavior Disorders
Using Mobile Technology to Enhance Multisystemic Therapy (MST) Outcomes
The goal of the current trial is to assess the feasibility of a newly developed prototype of a cell phone app called VillageWhere.
- Trial name
- VillageWhere (NCT02320903)
- Testing
- VillageWhere App
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Evidence-Based Practice Institute, Seattle, WA
Attention Deficit Disorder With Hyperactivity
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
This study will assess the safety and tolerability of MTS while attempting to establish the appropriate starting dose for subjects previously on an existing long-acting methylphenidate product.
- Trial name
- NCT00151983
- Testing
- Methylphenidate Transdermal System
- Where
- 18 sites in United States
- Volunteers
- 175 people
- Sponsor
- Noven Therapeutics
Autism Spectrum Disorder
Study to Assess the Janssen Autism Knowledge Engine in Participants With Autism Spectrum Disorder and in a Normally Developing Cohort
The purpose of this study is to evaluate the utility of and to clinically validate the Autism Behavior Inventory (ABI) in measuring clinical symptoms of Autism Spectrum Disorder (ASD) compared with other gold standard measures.
- Trial name
- NCT02668991
- Where
- 9 sites in United States
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Autism Spectrum Disorders, Stable Clinical Condition in the Last 3 Months
Early Nutritional Intervention in Patients With Autism Spectrum Disorders
Nutritional supplements like vitamin B6 and magnesium have demonstrated to have beneficial effects in patients with autism spectrum disorders (ASD).
- Trial name
- NCT01230359
- Testing
- Pyridoxine hydrochloride, Tang orange powder
- Where
- Qatar
- Volunteers
- 40 people
- Sponsor
- Hamad Medical Corporation
Attention-Deficit/Hyperactivity Disorder (ADHD)
Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
This was a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group, dose-ranging study to assess the efficacy and safety of SPN-812 (Viloxazine Extended-release Capsule) in children 6-12 years of age with…
- Trial name
- NCT02633527
- Testing
- 100mg SPN-812, 200mg SPN-812, 300mg SPN-812
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Autism Spectrum Disorder, Developmental Disorder
Children's Autism Metabolome Project
Development and Clinical Evaluation of the Stemina Metabolic Biomarker-Based Test to Diagnose Autism Spectrum Disorder in Early Childhood.
- Trial name
- CAMP-01 (NCT02548442)
- Where
- 8 sites in United States
- Volunteers
- 1,102 people, healthy volunteers welcome
- Sponsor
- Stemina Biomarker Discovery, Inc.
Attention Deficit-Hyperactivity Disorder
Real World Evidence of the Efficacy and Safety of FOQUEST
This study is a four-month, phase IV, open-label study of ADHD symptomatology and functional outcomes in pediatric (6 to 17 years old) and adult (≥18 years or older) patients with ADHD treated with FOQUEST or VYVANSE.
- Trial name
- reFOQus (NCT04152629)
- Testing
- Methylphenidate Hydrochloride, Lisdexamfetamine Dimesylate
- Where
- 12 sites in Canada
- Volunteers
- 257 people
- Sponsor
- Purdue Pharma, Canada
Oral Health, Intellectual Disability
Supervised Brushing Programme for Intellectual Disabled Students
Intellectual disabled persons faced more dental problems. According to a medical review paper of international and local studies, this group has poorer dental hygiene, more severe gum disease and more untreated caries.
- Conditions
- Oral Health, Intellectual Disability, Randomized Controlled Trial
- Trial name
- NCT03234231
- Testing
- 3-month supervised tooth brushing programme, oral health education talk
- Volunteers
- 602 people
- Sponsor
- MD Equation
Attention-Deficit/Hyperactivity Disorder (ADHD)
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory…
- Trial name
- NCT00776009
- Testing
- Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
- Where
- 8 sites in United States
- Volunteers
- 165 people
- Sponsor
- Novartis Pharmaceuticals
Autism Spectrum Disorder
A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children
1. Study purpose: To demonstrate the superiority of AST-001 compared to placebo in improving core symptoms of autism spectrum disorder (ASD) in children with ASD. 2.
- Trial name
- NCT06333964
- Testing
- AST-001
- Where
- 11 sites in South Korea
- Volunteers
- 169 people
- Sponsor
- Astrogen, Inc.
Tourette Syndrome
Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome
This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to assess the safety, efficacy, tolerability and steady-state plasma trough concentration of flexible-dosed aripiprazole once-daily…
- Trial name
- NCT03487783
- Testing
- Aripiprazole Oral Solution
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Otsuka Beijing Research Institute
Autistic Disorder
Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).
This study will compare the effectiveness (how well the drug works) of aripiprazole, flexibly dosed with a placebo, in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).
- Trial name
- NCT00332241
- Testing
- Aripiprazole
- Where
- 9 sites in United States
- Volunteers
- 98 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Autism Spectrum Disorder
Study to Evaluate the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder
The purpose of this study is to assess the usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in autism spectrum disorder (ASD) (severe abnormalities in the development of many basic…
- Trial name
- Mentis (NCT02299700)
- Testing
- No Intervention
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Janssen Research & Development, LLC
Attention Deficit Hyperactivity Disorder
Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine
The purpose of this trial is to test the value of dose increases in patients with residual ADHD symptoms after treatment with the usual target dose of atomoxetine
- Trial name
- NCT00485407
- Testing
- Atomoxetine Hydrochloride
- Where
- 2 sites in United States, Canada
- Volunteers
- 377 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder With Hyperactivity
Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17
The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.
- Trial name
- NCT00150592
- Testing
- SPD503 (Guanfacine HCl)
- Volunteers
- 182 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
The study will evaluate the efficacy of LDX treatment group compared to placebo on the change from Baseline ADHD-RS-IV score at endpoint.
- Trial name
- NCT00735371
- Testing
- LDX 30 mg, LDX 50 mg, LDX 70 mg
- Where
- 45 sites in United States
- Volunteers
- 314 people
- Sponsor
- Shire
Autism Spectrum Disorder
A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)
For participants enrolled prior to Version 6 of the protocol: This was a Phase II multi-center, randomized, double-blind, 24-week, 3-arm, parallel group, placebo-controlled study to investigate the efficacy, safety, and…
- Trial name
- NCT02901431
- Testing
- RO5285119
- Where
- 45 sites in United States
- Volunteers
- 339 people
- Sponsor
- Hoffmann-La Roche
Attention Deficit/Hyperactivity Disorder
Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children
The purpose of this study is to assess the long-term safety of Adhansia XR in children and to characterize the pharmacokinetics (PK) in 4 to 5 year-olds.
- Trial name
- NCT04987762
- Testing
- Adhansia XR
- Where
- 15 sites in United States
- Volunteers
- 103 people
- Sponsor
- Purdue Pharma LP
ADHD
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
This study is a Phase 3, multi-center, open-label trial to evaluate the long-term safety of solriamfetol in children and adolescents with ADHD.
- Trial name
- NCT07773883
- Testing
- Solriamfetol
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- Axsome Therapeutics, Inc.
Attention Deficit Hyperactivity Disorder, Dyslexia
Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
This study will evaluate the effects of atomoxetine on brain activation during attention and reading tasks via functional Magnetic Resonance Imaging (fMRI) in participants ages 10 to 16 years old with ADHD and comorbid dyslexia
- Trial name
- NCT00716274
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company